Generated by AI
iShares U.S. Pharmaceuticals ETF is an exchange-traded fund that seeks to track the investment results of the Dow Jones U.S. Select Pharmaceuticals Index, providing investors with exposure to U.S. pharmaceutical companies. The fund holds a diversified portfolio of established pharmaceutical firms engaged in drug discovery, development, manufacturing, and distribution across therapeutic areas. As a cap-weighted index fund, it emphasizes larger pharmaceutical companies while maintaining broad sector coverage. The ETF offers quarterly dividend distributions and charges a low expense ratio, making it an accessible vehicle for investors seeking targeted exposure to the pharmaceutical industry. The fund serves both individual and institutional investors looking to gain equity exposure to the U.S. pharmaceutical sector without holding individual pharmaceutical stocks.
The latest articles about IHE.
iShares offers lower fees and smoother returns, while First Trust provides concentrated biotech exposure with higher growth potential.
IHE offers lower costs and higher income through a concentrated play on established drugmakers, while IBB provides broader exposure to 243 biotech firms with higher volatility.
IHE has outperformed recently by concentrating in U.S. drugmakers. PPH offers global reach and a higher dividend for investors willing to trade some of that momentum for income.
Smart Beta ETF report for FTXH
Summary of Jan 29's posts. Generated by AI.
No summary yet.
No summary yet.
No summary yet.
No summary yet.
Investors talking about IHE also mention these. Each card shows that asset’s own numbers for the past 24 hours.